Stanford University
Showing 2,121-2,140 of 3,514 Results
-
Kelley M. Skeff, MD, PhD
George DeForest Barnett Professor of Medicine
Current Research and Scholarly InterestsDevelopment and evaluation of improved teaching methods; assessment of teacher's attitudes toward their teaching role; study of clinical teaching; evaluation of alternative methods of learning in clinical clerkships (e.g. computer assisted instruction, video tape review, etc.).
-
Eila C. Skinner
Thomas A. Stamey Research Professor of Urology
Current Research and Scholarly InterestsMy research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.
-
Lawrie Skinner
Clinical Associate Professor, Radiation Oncology - Radiation Physics
BioLawrie Skinner, PhD DABR is a therapeutic medical physicist with clinical expertise in external beam radiation therapy, including advanced motion management techniques and MRI-guided radiation therapy.
Research interests generally revolve around developing novel devices for advanced clinical practice. Examples include personalized 3D printed electron beam collimators, rotating couch overlays for total body radiation therapy, and radiotransparent audio visual communication and immersion displays.
Dr skinner also has a research background in synchrotron x-ray scattering, neutron scattering, molecular dynamics and Monte Carlo computational modelling. -
Stephen Skirboll
Associate Professor of Neurosurgery
Current Research and Scholarly InterestsMy research focuses on screening strategies to identify and characterize cancer stem cells (CSCs) in human gliomas. We are pursuing this in several ways: 1) a novel colony-forming antibody live cell array to identify distinct CSC surface phenotypes, 2) RNAi screens to identify kinases critical for CSC tumorigenicity, 3) high throughput small molecule and chemical screens to identify compounds that selectively kill or target CSCs, and 4) identifying CSCs using the tumor specific EGFRvIII
